businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)4 months ago
businesswire.comATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm5 months ago
businesswire.comAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)5 months ago
businesswire.comAtara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference7 months ago
businesswire.comAtara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference7 months ago
businesswire.comAtara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference7 months ago
businesswire.comAtara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress7 months ago
businesswire.comAtara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 20248 months ago
businesswire.comAtara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)9 months ago
CashuAtara Biotherapeutics: Overview and Latest Developments in Biopharmaceutical Innovations.3 days ago
CashuAtara Biotherapeutics Boosts T-Cell Immunotherapy with New Hiring and RSU Initiatives4 months ago